Therefore, targeting GnT-V, SPARC, SNAIL, MITF in combination with CAR T cells that are specific to surface proteins of MTFs (macrophage-tumor fusion cells), such as β1,6-branched oligosaccharides, MET and LAMP1 may improve CAR T cell performance in metastatic melanoma by eliminating leukocyte-cancer fusion cells. The gene discussed is SPARC; the disease is neoplasm.